Table 2.
Change in the mean ESMO-MCBS and ASCO-VF NHB scores
| Time 1 | Time 2 | Mean difference | p value | |||
|---|---|---|---|---|---|---|
| Number of trials (%) | Mean score | Number of trials (%) | Mean score | |||
| ESMO-MCBS | ||||||
| ESMO-MCBS score | 24 (100.0) | 3.29 | 24 (100.0) | 3.54 | + 0.25 | 0.137 |
| Preliminary score | 24 (100.0) | 3.04 | 24 (100.0) | 3.08 | + 0.04 | 0.747 |
| Bonus score | 10 (41.7) | 0.25 | 11 (45.8) | 0.46 | + 0.21 | 0.057 |
| QoL upgrade | 4 (16.7) | 0.17 | 8 (33.3) | 0.33 | ||
| Toxicity upgrade | 6 (25.0) | 0.25 | 7 (29.2) | 0.29 | ||
| Downgrade for PFS advantage only | 1 (4.2) | − 0.04 | – | – | ||
| Toxicity downgrade | 1 (4.2) | − 0.04 | – | – | ||
| ASCO-VF NHB | ||||||
| ASCO-VF NHB score | 22 (100.0) | 46.68 | 22 (100.0) | 49.98 | + 3.30 | 0.081 |
| Clinical benefit score | 22 (100.0) | 33.66 | 22 (100.0) | 34.09 | + 0.43 | 0.621 |
| Toxicity score | 22 (100.0) | − 2.88 | 22 (100.0) | − 3.20 | − 0.32 | 0.169 |
| Bonus score | 19 (86.4) | 15.91 | 20 (90.9) | 19.09 | + 3.18 | 0.050 |
| OS tail of curve | 4 (18.2) | 3.64 | 3 (13.6) | 2.73 | ||
| PFS tail of curve | 10 (45.5) | 7.27 | 10 (45.5) | 7.27 | ||
| Palliation | 6 (27.3) | 2.73 | 11 (50.0) | 5.00 | ||
| QoL | 5 (22.7) | 2.27 | 9 (40.9) | 4.09 | ||
QoL quality of life, OS overall survival, PFS progression-free survival